(Q90641033)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

title

Miliary tuberculosis developing during adalimumab treatment for Behçet's disease with uveitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

1 reference

1 reference

1 reference

Minji Jennifer Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

Nicholas Jones

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

Laura R Steeples

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

publication date

4 December 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

Rifampicin reduces effectiveness and bioavailability of prednisolone.

15 April 2020

cites work

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

12 December 2020

The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU).

1 reference

12 December 2020

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

1 reference

12 December 2020

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

1 reference

12 December 2020

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

1 reference

12 December 2020

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

1 reference

12 December 2020

Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors

1 reference

12 December 2020

Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials

1 reference

12 December 2020

Toxic optic neuropathies: an updated review

1 reference

12 December 2020

Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency.

1 reference

12 December 2020

Tumor necrosis factor inhibitors - state of knowledge

1 reference

12 December 2020

Oral Fluoroquinolones and the Risk of Uveitis

1 reference

12 December 2020

Sepsis During Immunosuppression for Sight-threatening Uveitis: The Flip side.

1 reference

12 December 2020

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

1 reference

12 December 2020

Adalimumab in Patients with Active Noninfectious Uveitis.

1 reference

12 December 2020

Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).

1 reference

12 December 2020

Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

1 reference

12 December 2020

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

1 reference

12 December 2020

Clinical Outcomes of Intravitreal Preservative-Free Triamcinolone Preparation (Triesence®) for Cystoid Macular Oedema and Inflammation in Patients with Uveitis.

1 reference

12 December 2020

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.

1 reference

12 December 2020

Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.

1 reference

12 December 2020

Identifiers

DOI

10.1136/BCR-2018-226772

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30567192%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference